Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab.
LRTI
RSV
bronchiolitis
cohort study
palivizumab
preterm
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
02
2022
accepted:
16
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Preterm infants are at risk of lower respiratory tract infections (LRTI), including Respiratory Syncytial Virus (RSV) associated bronchiolitis, for which palivizumab prophylaxis can be proposed. Our aim was to determine risk factors of very severe RSV disease in children born before 34 weeks of gestation. Among 2,101 infants born before 34 weeks of gestation in 3 maternity wards between 2012 and 2017, the laboratory confirmed RSV-infected patients requiring hospitalization before 12 months of corrected age were retrospectively included. We collected data about the neonatal period, the palivizumab prophylaxis and the hospitalization for a RSV-related LRTI. LRTI was considered as very severe (VS-LRTI) when patients required invasive or non-invasive positive pressure ventilation. Among 86 included patients, 31 met the criteria of VS-LRTI. The VS-LRTI patients had a higher birth gestational age and weight but less heart disease and bronchopulmonary dysplasia. They received palivizumab prophylaxis less frequently than the other patients but the difference was not significant. At the onset of infection, VS-LRTI patients had a younger corrected age for prematurity and presented more frequently with apnea, bradycardia, life-threatening event, hemodynamic failure, hypercapnia. Using logistic regression, the main factor associated with VS-LRTI was a younger corrected age for prematurity at the onset of infection [Odd ratio for each month of corrected age = 0.77 (0.62; 0.93), Infants at the highest risk of VS-LRTI were infants with a younger corrected age for prematurity. Therefore, a better targeting of infants requiring palivizumab prophylaxis and early interventions at hospital discharge could limit VS-LRTI in these infants.
Identifiants
pubmed: 35874569
doi: 10.3389/fped.2022.884120
pmc: PMC9301069
doi:
Types de publication
Journal Article
Langues
eng
Pagination
884120Informations de copyright
Copyright © 2022 Mulot, Benchaib, Plaisant, Ploin, Gillet, Javouhey, Claris, Picaud, Casalegno and Butin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Respir Crit Care Med. 2019 Sep 15;200(6):659-660
pubmed: 31091958
J Infect Dis. 2020 Sep 1;222(7):1129-1137
pubmed: 32006428
J Pediatr. 2003 Nov;143(5 Suppl):S118-26
pubmed: 14615710
J Infect Dis. 2020 Sep 1;222(7):1070-1072
pubmed: 32006425
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296674
Eur J Pediatr. 2021 Jun;180(6):1833-1840
pubmed: 33527179
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Vaccine. 2018 Oct 29;36(45):6591-6593
pubmed: 30266485
Arch Pediatr. 2020 Jan;27(1):39-44
pubmed: 31780096
Eur J Pediatr. 2011 Jul;170(7):907-13
pubmed: 21174120
Eur J Pediatr. 2018 Jun;177(6):913-920
pubmed: 29654399
J Infect Dis. 1997 Apr;175(4):814-20
pubmed: 9086135
PLoS One. 2016 Jun 16;11(6):e0157446
pubmed: 27310438
J Gen Virol. 1983 Sep;64 (Pt 9):1867-76
pubmed: 6886679
Paediatr Child Health. 1998 Nov;3(6):402-4
pubmed: 20401222
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602
pubmed: 23633336
Eur J Pediatr. 1998 Apr;157(4):331-5
pubmed: 9578972
Pediatr Pulmonol. 2017 Apr;52(4):556-569
pubmed: 27740723
Transbound Emerg Dis. 2022 Jul;69(4):e871-e882
pubmed: 34730277